Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor

被引:5
|
作者
Burmeister, M. A. [1 ]
Bracy, D. P. [2 ]
James, F. D. [2 ]
Holt, R. M. [1 ]
Ayala, J. [1 ]
King, E. M. [3 ]
Wasserman, D. H. [2 ]
Drucker, D. J. [4 ]
Ayala, J. E. [1 ,3 ]
机构
[1] Sanford Burnham Med Res Inst Lake Nona, Diabet & Obes Res Ctr, Metab Signaling & Dis Program, Orlando, FL 32827 USA
[2] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA
[3] Sanford Burnham Med Res Inst Lake Nona, Cardiometab Phenotyping Core, Orlando, FL 32827 USA
[4] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
来源
JOURNAL OF PHYSIOLOGY-LONDON | 2012年 / 590卷 / 20期
基金
美国国家卫生研究院;
关键词
INSULIN-SECRETION; GLP-1; RECEPTORS; ENERGY-BALANCE; INCRETIN; METABOLISM; MICE; SUPPRESSION; SENSITIVITY; MUSCLE; AMIDE;
D O I
10.1113/jphysiol.2012.234914
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Key points Glucagon-like peptide-1 (Glp1) regulates hepatic glucose production (HGP) and muscle glucose uptake (MGU) via its ability to stimulate insulin secretion. Using exercise as a means to stimulate glucose flux independently of insulin secretion, we observed that Glp1 receptor (Glp1r) knockout (Glp1r-/-) mice become hyperglycaemic but display normal rates of MGU. Since euglycaemia during exercise is typically maintained by matching rates of HGP to rates of MGU, we hypothesize that exercise-induced hyperglycaemia in Glp1r-/- mice is due to excessive HGP. Using innovative catheterization and isotope dilution techniques, we demonstrate that hyperglycaemia in exercising Glp1r-/- mice is associated with excessive HGP and glucagon secretion. These results suggest an essential and novel role for basal Glp1r signalling in the suppression of alpha cell secretion during exercise. Abstract In response to oral glucose, glucagon-like peptide-1 receptor (Glp1r) knockout (Glp1r-/-) mice become hyperglycaemic due to impaired insulin secretion. Exercise also induces hyperglycaemia in Glp1r-/- mice. In contrast to oral glucose, exercise decreases insulin secretion. This implies that exercise-induced hyperglycaemia in Glp1r-/- mice results from the loss of a non-insulinotropic effect mediated by the Glp1r. Muscle glucose uptake (MGU) is normal in exercising Glp1r-/- mice. Thus, we hypothesize that exercise-induced hyperglycaemia in Glp1r-/- mice is due to excessive hepatic glucose production (HGP). Wild-type (Glp1r+/+) and Glp1r-/- mice implanted with venous and arterial catheters underwent treadmill exercise or remained sedentary for 30 min. [3-3H]glucose was used to estimate rates of glucose appearance (Ra), an index of HGP, and disappearance (Rd). 2[14C]deoxyglucose was used to assess MGU. Glp1r-/- mice displayed exercise-induced hyperglycaemia due to an excessive increase in Ra but normal Rd and MGU. Exercise-induced glucagon levels were 2-fold higher in Glp1r-/- mice, resulting in a 2-fold higher glucagon:insulin ratio. Since inhibition of the central Glp1r stimulates HGP, we tested whether intracerebroventricular (ICV) infusion of the Glp1r antagonist exendin(939) (Ex9) in Glp1r+/+ mice would result in exercise-induced hyperglycaemia. ICV Ex9 did not enhance glucose levels or HGP during exercise, suggesting that glucoregulatory effects of Glp1 during exercise are mediated via the pancreatic Glp1r. In conclusion, functional disruption of the Glp1r results in exercise-induced hyperglycaemia associated with an excessive increase in glucagon secretion and HGP. These results suggest an essential role for basal Glp1r signalling in the suppression of alpha cell secretion during exercise.
引用
收藏
页码:5245 / 5255
页数:11
相关论文
共 50 条
  • [31] Amino acids are sensitive glucagon receptor-specific biomarkers for glucagon-like peptide-1 receptor/glucagon receptor dual agonists
    Li, Wenyu
    Kirchner, Thomas
    Ho, George
    Bonilla, Fany
    D'Aquino, Katharine
    Littrell, James
    Zhang, Rui
    Jian, Wenying
    Qiu, Xi
    Zheng, Songmao
    Gao, Bin
    Wong, Peggy
    Leonard, James N.
    Camacho, Raul C.
    DIABETES OBESITY & METABOLISM, 2020, 22 (12) : 2437 - 2450
  • [32] Glucagon-Like Peptide-1 Agonists
    Stanton, Eloise W.
    Manasyan, Artur
    Banerjee, Rakhi
    Hong, Kurt
    Koesters, Emma
    Daar, David A.
    ANNALS OF PLASTIC SURGERY, 2025, 94 (01) : 121 - 127
  • [33] Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
    McKay, Naomi J.
    Kanoski, Scott E.
    Hayes, Matthew R.
    Daniels, Derek
    AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2011, 301 (06) : R1755 - R1764
  • [34] A role for Glucagon-Like Peptide-1 in the regulation of β-cell autophagy
    Arden, Catherine
    PEPTIDES, 2018, 100 : 85 - 93
  • [35] Attenuated diuresis and natriuresis in response to glucagon-like peptide-1 in hypertensive rats are associated with lower expression of the glucagon-like peptide-1 receptor in the renal vasculature
    Savignano, Fernanda A.
    Crajoinas, Renato O.
    Pacheco, Bruna P. M.
    Campos, Luciene C. G.
    Shimizu, Maria Heloisa M.
    Seguro, Antonio Carlos
    Girardi, Adriana C. C.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2017, 811 : 38 - 47
  • [36] A role for central glucagon-like peptide-1 in temperature regulation
    OShea, D
    Gunn, I
    Chen, XH
    Bloom, S
    Herbert, J
    NEUROREPORT, 1996, 7 (03) : 830 - 832
  • [37] Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists
    Chen, J.
    Cooper, M. E.
    Coughlan, M. T.
    DIABETES & METABOLISM, 2025, 51 (03)
  • [38] Signal transduction and desensitization of the glucagon-like peptide-1 receptor
    Thorens, B
    Widmann, C
    ACTA PHYSIOLOGICA SCANDINAVICA, 1996, 157 (03): : 317 - 319
  • [39] Glucagon-like peptide-1 receptor expression in the human eye
    Hebsgaard, Josephine B.
    Pyke, Charles
    Yildirim, Emre
    Knudsen, Lotte B.
    Heegaard, Steffen
    Kvist, Peter H.
    DIABETES OBESITY & METABOLISM, 2018, 20 (09) : 2304 - 2308
  • [40] Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin
    Bahne, Emilie
    Hansen, Morten
    Bronden, Andreas
    Sonne, David P.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETES OBESITY & METABOLISM, 2016, 18 (10) : 955 - 961